News & Updates

In chronic hepatitis B (CHB) patients treated with pegylated interferon alpha (peg-IFN-α)-based interventions, lower levels of the HB core-related antigen (HBcrAg) and higher levels of the HB surface antibody (HbsAb) are associated with durable functional cure, a recent study has found,

Supplementation with lutein/zeaxanthin instead of beta carotene is safe and does not contribute to an increase in lung cancer risk while having a potential beneficial effect on the risk of progression to late age-related macular degeneration (AMD), according to data from the Age-Related Eye Disease Study 2 (AREDS2) study.

Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.

Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.

A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.